Author Correction: Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation

Chengyu Shi, Ying Wang, Minjie Wu, Yu Chen, Fangzhou Liu, Zheyuan Shen, Yiran Wang, Shaofang Xie, Yingying Shen, Lingjie Sang, Zhen Zhang, Zerui Gao, Luo-jia Yang, Lei Qu, Zuozhen Yang, Xinyu He, Yu Guo, Chenghao Pan, Jinxin Che, Huai‐Qiang Ju, Jian Liu, Zhijian Cai, Qingfeng Yan, Luyang Yu, Liangjing Wang, Xiaowu Dong, Pinglong Xu, Jianzhong Shao, Yang Liu, Xu Li, Wenqi Wang, Ruhong Zhou, Tianhua Zhou, Aifu LinNature Communications 2024 · DOI · OpenAlex

Abstract

This formal correction addresses a data presentation error in the original article published in Nature Communications. Specifically, a western blot image for PD-L1 in Figure 6k was inadvertently duplicated from Figure 3j. The corrected Figure 6k provided here confirms the original scientific conclusions regarding the role of TMUB1 and the E3 ligase HUWE1 in regulating PD-L1 stability.

Introduction

Cancer cells frequently exploit the PD-L1 (Programmed Death-Ligand 1) checkpoint to evade immune surveillance. The stability and cell-surface presence of PD-L1 are tightly regulated by post-translational modifications, including polyubiquitination and glycosylation. This research identifies TMUB1 (Transmembrane and Ubiquitin-like domain-containing protein 1) as a key scaffold protein that modulates these processes, thereby controlling anti-tumor immunity.

Mapping the TMUB1-PD-L1 Interaction

To understand how TMUB1 regulates PD-L1, researchers mapped the physical interaction between the two proteins. Using various deletion mutants, they identified that the UBL (Ubiquitin-like) domain of TMUB1, specifically residues 88-102, is critical for binding to PD-L1.

Schematic of TMUB1 domains and the identified PD-L1 binding site (residues 88-102).

Mechanism of PD-L1 Degradation

The study reveals that TMUB1 facilitates the recruitment of HUWE1, an E3 ubiquitin ligase, to PD-L1. This recruitment leads to the polyubiquitination and subsequent proteasomal degradation of PD-L1. A synthetic peptide, PTPR, was designed to mimic the binding interface and modulate this pathway.

The corrected data in Figure 6k demonstrates that PTPR treatment enhances the interaction between HUWE1 and PD-L1, promoting PD-L1 degradation. This mechanism is summarized in the model shown in Figure 6l.

Corrected Figure 6 detailing the biochemical interaction between PTPR, HUWE1, and PD-L1 (k), the proposed mechanistic model (l), and the resulting functional enhancement of T-cell-mediated tumor cell killing (m-o).

Functional Impact on Anti-Tumor Immunity

The functional consequences of targeting the TMUB1-PD-L1 axis were evaluated using co-culture assays with MDA-MB-231 breast cancer cells and T cells. PTPR treatment significantly reduced tumor cell survival (Fig. 6m) and boosted the expression of key pro-inflammatory cytokines, IFN-γ and TNF-α (Fig. 6n, o). These results suggest that disrupting the TMUB1-mediated stabilization of PD-L1 can effectively "unmask" tumor cells to the immune system.

Conclusion

The correction of Figure 6k ensures the accuracy of the biochemical evidence supporting the TMUB1-HUWE1-PD-L1 regulatory axis. These findings highlight TMUB1 as a promising therapeutic target for enhancing the efficacy of cancer immunotherapies by promoting the natural degradation of immune checkpoints.

Summary updated

Abstract

The original version of this Article contained an error in Fig. 6k, in which a duplicate western blot image for PD-L1 from Fig. 3j was re-used inadvertently.
BibTeX
@inproceedings{shi2024author,
  author = {Chengyu Shi and Ying Wang and Minjie Wu and Yu Chen and Fangzhou Liu and Zheyuan Shen and Yiran Wang and Shaofang Xie and Yingying Shen and Lingjie Sang and Zhen Zhang and Zerui Gao and Luo-jia Yang and Lei Qu and Zuozhen Yang and Xinyu He and Yu Guo and Chenghao Pan and Jinxin Che and Huai‐Qiang Ju and Jian Liu and Zhijian Cai and Qingfeng Yan and Luyang Yu and Liangjing Wang and Xiaowu Dong and Pinglong Xu and Jianzhong Shao and Yang Liu and Xu Li and Wenqi Wang and Ruhong Zhou and Tianhua Zhou and Aifu Lin},
  title = {{Author Correction: Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-024-55049-5},
}
Figure